Transplantation and Cellular Therapy最新文献

{"title":"Peripheral blood or bone marrow grafts for mismatched unrelated donors with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis.","authors":"Leonardo Javier Arcuri, Victor Hugo Glasser Natal, Mariana Nassif Kerbauy, Guilherme Fleury Perini, Fabio Pires de Souza Santos, Andreza Alice Feitosa Ribeiro, Carla de Oliveira Ribeiro, Nelson Hamerschlak","doi":"10.1016/j.jtct.2025.10.012","DOIUrl":"https://doi.org/10.1016/j.jtct.2025.10.012","url":null,"abstract":"<p><strong>Introduction: </strong>Peripheral blood stem cell (PBSC) grafts are generally considered a risk factor for graft-versus-host disease (GVHD) compared to bone marrow (BM) in hematopoietic cell transplantation (HCT). High-dose posttransplant cyclophosphamide (PTCy), originally introduced for T-cell replete haploidentical transplantation, has become more widely used in matched unrelated donor (MUD) and mismatched unrelated donor (MMUD) transplants with PB, and has been shown to reduce the difference between MUD and MMUD. Despite this progress, the comparative impact of PBSC versus BM in this specific setting remains unclear.</p><p><strong>Methods: </strong>We aimed to compare outcomes between PBSC and BM as graft sources in patients undergoing hematopoietic cell transplantation with HLA 7/8 mismatched unrelated donors (MMUD) receiving PTCy-based prophylaxis. We used data collected by the CIBMTR. The primary outcomes were overall survival (OS) and systemic immunosuppressive therapy-requiring chronic GVHD (IST-R cGVHD).</p><p><strong>Results: </strong>With a median follow-up of 36 months, 709 patients received PBSC and 171 received BM from MMUD. Both groups were quite comparable. In univariable analyses, 3-year OS was similar between PBSC (57%, 95% CI 53-61) and BM (58%, 95% CI 51-66 for BM, p = 0.63), As well as IST-R cGVHD (30%, 95% CI 26-33, compared to 25%, 95% CI 19-32, p = 0.25). Other secondary outcomes showed no statistical difference. In multivariable analyses, PBSC was not associated with a different overall survival (HR = 0.96, 95% CI 0.74-1.25, p = 0.78) or IST-R cGVHD (HR = 1.40, 95% CI 0.99-1.98, p = 0.054). However, all grades of cGVHD were significantly higher with PBSC (HR = 1.46, 95% CI 1.06-2.00, p = 0.019). Other outcomes did not differ statistically in multivariable analysis.</p><p><strong>Discussion: </strong>Our results indicate no significant difference in the primary outcomes between bone marrow and peripheral blood in mismatched, HLA 7/8 unrelated transplants with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis. This challenges the historical belief that BM leads to better outcomes in unrelated donor settings, compared with PBSC. Until randomized studies indicate otherwise, choosing graft sources can reasonably focus on donor convenience and logistical feasibility.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment outcome of defibrotide for treatment of severe hepatic VOD/SOS after hematopoietic cell transplantation.","authors":"Jae-Ho Yoon, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho","doi":"10.1016/j.jtct.2025.10.003","DOIUrl":"https://doi.org/10.1016/j.jtct.2025.10.003","url":null,"abstract":"<p><p>Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious complication following hematopoietic cell transplantation (HCT), with markedly poor prognosis in patients with severe or very severe presentations. Defibrotide (DF) is the only approved treatment for severe to very severe VOD/SOS, but real-world evidence remains limited, particularly in East Asian populations. We retrospectively analyzed 73 adult patients with severe or very severe VOD/SOS treated with DF between 2016 and 2023 at a single tertiary center in Korea. Diagnosis and grading were based on the revised EBMT criteria. During the study period, national reimbursement guidelines for DF evolved from requiring ≥4 of 6 to ≥2 of 5 severity criteria, allowing earlier treatment initiation. The median time from HCT to VOD/SOS diagnosis was 24 days (range, D-1 to D+843), and DF was administered within a median of 1 day after diagnosis. At DF initiation, 40 patients were classified as severe and 33 as very severe; disease progression resulted in 53 patients reaching the very severe category. The overall response rate was 46.5%, and complete resolution was achieved in 39.7% of cases. The 100-day overall survival (OS) was 34.2%, significantly higher among patients receiving DF within 2 days of diagnosis (36.0% vs. 17.4%, p=0.049). High total bilirubin levels at diagnosis and at the worst disease period were strongly associated with poor long-term survival regardless of severity criteria. These data provide real-world support for the early use of DF and suggest the prognostic utility of bilirubin levels in guiding treatment for VOD/SOS following HCT.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treosulfan-based conditioning ameliorates impact of pretransplant MRD-positivity in AML patients allografted in remission.","authors":"Jacob Pyka, Judith Metzdorf, Christian Reicherts, Julia Marx, Nils Leimkühler, Artur Schneider, Jennifer Kaivers, Annemarie Mohring, H Christian Reinhardt, Matthias Stelljes, Thomas Schroeder, Christina Rautenberg","doi":"10.1016/j.jtct.2025.10.011","DOIUrl":"https://doi.org/10.1016/j.jtct.2025.10.011","url":null,"abstract":"<p><strong>Background: </strong>Based on the MC-FludT.14/L phase III trial Treosulfan-based conditioning has become an established regimen in allogeneic hematopoetic stem cell transplantation (allo-HCT) for older or comorbid acute myeloid leukemia (AML) patients due to its reduced toxicity and sufficient antileukemic efficacy.</p><p><strong>Objective: </strong>In this real-world (RW) analysis, we aimed to validate these findings and assess the prognostic impact of several patient-, disease- and transplant-related parameters, especially measurable residual disease (MRD) positivity prior to transplant, on posttransplant outcome after Treosulfan-based conditioning.</p><p><strong>Study design: </strong>We conducted a retrospective analysis of 102 patients who received conditioning with 10g/m²Treosulfan and Fludarabin (Flu/Treo10) in 1^st / 2^nd complete remission (CR) with available pretransplant MRD status.</p><p><strong>Results: </strong>In our real-world Flu/Treo10-cohort, 3-year (yr) 3-year overall (OS) and relapse-free survival (RFS), relapse incidence (CIR) and non-relapse mortality (NRM) were 68%, 53%, 38% and 8%, thus comparable to the randomized-controlled trial (RCT). In contrast to common expectations, MRD positivity was not associated with adverse outcome, but we could identify the presence of secondary AML (sAML) and/or a complex karyotype (cKT) at diagnosis as adverse prognostic predictors for posttransplant outcome and confirmed these findings in a validation cohort.</p><p><strong>Conclusion: </strong>In this analysis we showed that Treosulfan-based conditioning enables reliable safety and efficacy in a RW cohort of elderly and/or comorbid AML patients allografted in CR. Furthermore, our analysis implies that disease-related risk features present at diagnosis may outweigh the impact of pretransplant MRD-status on posttransplant outcome after Treosulfan-based conditioning.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145287181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR-T for management of R/R PTLD following lung transplant: A multi-center retrospective study.","authors":"Brittany Salter, Adam Suleman, Robert Kridel, Amy M Trottier, Regina Li, Matthew Binnie, Amaris K Balitsky, Gwynivere A Davies","doi":"10.1016/j.jtct.2025.10.006","DOIUrl":"https://doi.org/10.1016/j.jtct.2025.10.006","url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145276067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies.","authors":"Asfand Yar Cheema, Hossam M Ali, Bibi Maryam, Muhammad Faisal Aslam, Praveena S Thiagarajan, Daniyal Shahid, Mishaal Munir, Ali Najam, Shahzad Raza, Faiz Anwer","doi":"10.1016/j.jtct.2025.09.044","DOIUrl":"https://doi.org/10.1016/j.jtct.2025.09.044","url":null,"abstract":"<p><p>Chimeric Antigen Receptor T cell (CAR-T) therapy has transformed the treatment of hematological malignancies. Autologous CAR-T therapies have shown remarkable efficacy but face multiple challenges, including the need to collect autologous T cell lymphocytes, logistical complexity, prolonged manufacturing time, inadequate quantity due to the collection of already exhausted cells from heavily treated patients, T cell quality not meeting the FDA specifications, and high costs, thereby limiting their widespread use. Allogeneic CAR-T (allo-CAR-T) therapy offers a promising alternative and several advantages, including immediate availability as an off-the-shelf product, standardized production that meets pre-defined quality standards, and potentially reduced costs. However, allo-CAR-T therapies encounter significant challenges, particularly the risk of graft-versus-host disease (GvHD), a clinically observed complication unless mitigating steps are taken, and host immune-mediated rejection, which can compromise their safety and effectiveness. Alternative approaches focus on gene-editing techniques and cell source modifications to maintain the efficacy of allo-CAR-Ts in hematologic malignancies while minimizing complications. Techniques such as CRISPR/Cas9-mediated disruption of TCR and HLA genes, the use of γδ T cells, and the overexpression of immunomodulatory proteins like CD47 offer promising strategies for creating safer and more effective CAR-T cell therapies. However, further research and clinical validation are necessary to optimize these approaches and minimize the risk of adverse immune reactions in patients. This review summarizes current advancements in gene editing, the use of CRISPR-Cas9 technology, innovations in lymphodepletion regimens, and strategies for overcoming graft rejection. We also dive into currently approved therapies, ongoing clinical trials, and future directions.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145275767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Toxicities of Bone Marrow Donation in Unrelated Donors with Sickle Cell Trait: A CIBMTR Analysis.","authors":"Nosha Farhadfar, Stephanie Bo-Subait, Gabrielle Schmidt, Brent Logan, Mahmoud Aljurf, Sherif Badawy, Amer Beitinjaneh, Lohith Gowda, Kimberly A Kasow, Matthew Seftel, Akshay Sharma, Hemalatha G Rangarajan, Megan Herr, Minoo Battiwalla, Bronwen Shaw, Heather E Stefanski","doi":"10.1016/j.jtct.2025.10.007","DOIUrl":"https://doi.org/10.1016/j.jtct.2025.10.007","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Ethnic minority donors are essential on international donor registries to ensure access to all patients requiring an allogeneic stem cell transplant. Current literature regarding bone marrow (BM) donation-associated pain and toxicity in donors with Sickle Cell trait (ST), a condition that disproportionally affects minorities, is very limited. Improved communication with potential donors with ST about donation-associated toxicities is important to address misconceptions about the donation and may increase the likelihood of participation by minority donors.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;The aim of this study was to determine the impact of ST on peri-collection pain and toxicities experienced by unrelated BM donors with ST.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Study design: &lt;/strong&gt;The study population comprised first-time unrelated donors with ST and subset of unrelated donors without ST from the United States whose BM donation was facilitated by NMDP between 2010 and 2019. Donors in the control group (donors without ST) were selected for propensity score matching based on age categories, sex, race/ethnicity and pre-donation skeletal pain. Logistic regression models were conducted to compare the donors with and without ST for pain and toxicities associated with donation adjusting for differences in donor characteristics. Descriptive statistics were used to report SAE. Univariate probabilities of complete recovery from donation were calculated using the Kaplan-Meier estimator.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 346 BM donors (87 with ST and 259 without ST) were included in this study. The majority of the donors were male (52%), African American (64%) and overweight or obese (77%) in both cohorts. Stem cell collection parameters including BM harvest volume, requirement for autologous blood transfusion post-harvest and duration of anesthesia were comparable between the two cohorts. Two days post-donation, 68.9% of BM donors with ST and 83.1% of BM donors without ST experienced skeletal pain (p&lt;0.01). Although, grade 1 pain was more common in donors without ST (51.4% vs. 35.6%), grade 2-4 pain was comparable between the two cohorts (P=0.98). At 1-month post donation, grade 2 to 4 pain was comparable between the donors with and without ST (p=0.25). By 6-months post donation, the rates of persistent pain were low at 5.7% and 6.5% in donors with or without ST. Donation-related Modified Toxicity Criteria (MTC) at 2 days post donation was comparable between donors with and without ST (P=0.59). The median times to recovery in donors with and without ST were 23.5 and 22.0 days, respectively. The rate of reported AEs was slightly higher in donors with ST (2.29%) compared to donors without ST (1.59%).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;BM donation appeared well tolerated in donors with ST with similar rates of post-donation pain and general symptoms compared with the donors without ST. BM donation has a small risk of perioperative mortalit","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145276060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR, Transplantation and Cellular Therapy, 31:8, August 2025, 505-532; Article Number: JTCT-S-25-00377.","authors":"Stephen R Spellman, Ke Xu, Temitope Oloyede, Kwang Woo Ahn, Othman Salim Akhtar, Yung-Tsi Bolon, Larisa Broglie, Jenni Bloomquist, Caitrin Bupp, Min Chen, Steven M Devine, Najla El Jurdi, Mehdi Hamadani, Mary Hengen, Anna H Huppler, Samantha Jaglowski, Michelle Kuxhausen, Stephanie J Lee, Amy Moskop, Kristin M Page, Marcelo C Pasquini, Waleska S Pérez, Rachel Phelan, Doug Rizzo, Wael Saber, Heather E Stefanski, Patricia Steinert, Eileen Tuschl, Alexis Visotcky, Rebecca Vogel, Jeffery J Auletta, Bronwen E Shaw, Mariam Allbee-Johnson","doi":"10.1016/j.jtct.2025.09.001","DOIUrl":"10.1016/j.jtct.2025.09.001","url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Size does not always matter: limited impact of donor-recipient weight difference on outcomes of adult allogeneic peripheral blood stem cell hematopoietic cell transplantation.","authors":"Caden Chiarello, Sihath Singhabahu, Mats Remberger, Carol Chen, Tommy Alfaro Moya, Eshrak Al-Shaibani, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Datt Law, Jeffrey H Lipton, Fotios V Michelis, Igor Novitzky-Basso, Auro Viswabandya, Jonas Mattsson, Ivan Pasic","doi":"10.1016/j.jtct.2025.10.002","DOIUrl":"https://doi.org/10.1016/j.jtct.2025.10.002","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Allogeneic hematopoietic cell transplantation (HCT) relies on careful donor selection to optimize outcomes and minimize complications such as graft-versus-host disease (GVHD). While human leukocyte antigen (HLA) matching remains central to donor selection, secondary characteristics such as age, sex, cytomegalovirus serostatus, and donor-recipient weight difference have become increasingly relevant. Previous studies have demonstrated a relationship between donor-recipient weight ratio and stem cell dose, which may, in turn, influence outcomes including engraftment, survival, relapse, and GVHD. Despite evidence suggesting that donor weight affects CD34+ cell dose per unit of recipient weight, the specific impact of donor-recipient weight difference on transplant outcomes remains unclear.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;This study aims to evaluate the effect of donor-recipient weight disparity on post-transplant outcomes in adult allogeneic HCT, thereby informing donor selection when multiple suitable donors are available.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Study design: &lt;/strong&gt;This retrospective cohort study included 841 consenting patients 18 years of age or older who underwent allogeneic HCT using peripheral blood stem cells (PBSC) as the source of graft at the Princess Margaret Hospital Cancer Centre between January 1, 2018, and April 30, 2023. Collected variables included patient and donor weight, clinical and demographic characteristics, transplant regimen details, engraftment time, stem cell dose, survival outcomes, incidence of GVHD, and secondary complications. Conditioning regimens and GVHD prophylaxis varied by donor type, with protocol changes implemented during the study period. Primary outcomes included overall survival (OS), relapse-free survival (RFS), non-relapse mortality (NRM), cumulative incidence of relapse, and incidence of GVHD, CMV and EBV reactivation, and bloodstream infections. Statistical analyses included Mann-Whitney U test, chi-squared test, Kaplan-Meier survival estimates with log-rank testing, and Cox proportional hazards modeling for univariate and multivariate analysis. All analyses were conducted using TIBCO Statistica® 13.5.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among 841 patients, the median donor-recipient weight difference was 1.3 kg (range: -82 kg to +128 kg). When donor-recipient weight difference was analyzed as a continuous variable, the use of heavier donors was associated with higher CD34+ dose (r=0.2956, P&lt;0.001) and increased risk of chronic GVHD (HR 1.07, P=0.036). Weight difference was not significantly associated with OS, RFS, relapse, or risk of acute GVHD. The use of heavier donors was associated with decreased risk of NRM in univariate (HR 0.93, P=0.05) and multivariate (HR 0.93, P&lt;0.05) analyses.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The use of heavier donors in PBSC allogeneic HCT is associated with higher CD34+ cell dose, but its impact on transplant outcomes is limited, being associated","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to <Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome><[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>.","authors":"Melissa R Hines, Tristan E Knight, Kevin O McNerney, Mark B Leick, Tania Jain, Sairah Ahmed, Matthew J Frigault, Joshua A Hill, Michael D Jain, William T Johnson, Yi Lin, Kris M Mahadeo, Gabriela M Maron, Rebecca A Marsh, Sattva S Neelapu, Sarah Nikiforow, Amanda K Ombrello, Nirav N Shah, Aimee C Talleur, David Turicek, Anant Vatsayan, Sandy W Wong, Marcela V Maus, Krishna V Komanduri, Nancy Berliner, Jan-Inge Henter, Miguel-Angel Perales, Noelle V Frey, David T Teachey, Matthew J Frank, Nirali N Shah","doi":"10.1016/j.jtct.2025.09.016","DOIUrl":"https://doi.org/10.1016/j.jtct.2025.09.016","url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145259217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of oral eicosapentaenoic acid on veno-occlusive disease/sinusoidal obstruction syndrome onset prevention: single-center retrospective analysis.","authors":"Yukihiro Miyazaki, Hiroshi Narumi, Taichi Azuma, Kazushi Tanimoto, Yuya Masuda, Junichi Kato, Tatsuya Konishi, Shogo Nabe, Masaki Maruta, Toshiki Ochi, Jun Yamanouchi, Katsuto Takenaka","doi":"10.1016/j.jtct.2025.10.004","DOIUrl":"https://doi.org/10.1016/j.jtct.2025.10.004","url":null,"abstract":"<p><p>Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious complication associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although ursodeoxycholic acid and defibrotide can reduce the risk of VOD/SOS, preventive efforts remain insufficient. In 2009, we began prescribing oral eicosapentaenoic acid (EPA) to mitigate post-transplant complications. Notably, no patients receiving EPA developed VOD/SOS. In this retrospective study, we analyzed 138 transplants from 123 patients who underwent allo-HSCT at Ehime University Hospital between April 2008 and June 2024. Ninety-one patients received EPA after allo-HSCT (EPA group), while 47 patients did not (no-EPA group). EPA was administered at a dose of 1800 mg/day, divided into 2 or 3 doses. All patients were taking ursodeoxycholic acid. VOD/SOS occurred in three patients in the no-EPA group (6.5%) and in none of the EPA group (P = 0.014). Early post-transplant mortality within 100 days did not differ significantly between groups. Although causal inference is limited by the retrospective design of the study, our findings suggest that EPA use may be associated with a lower incidence of VOD/SOS. These findings warrant prospective, multicenter trials to determine whether EPA can improve transplant outcomes by reducing the incidence of VOD/SOS.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145245159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}